244 related articles for article (PubMed ID: 21707574)
1. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
[TBL] [Abstract][Full Text] [Related]
2. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
3. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
7. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Neuber B; Herth I; Tolliver C; Schoenland S; Hegenbart U; Hose D; Witzens-Harig M; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunol; 2011 Jul; 187(2):1047-56. PubMed ID: 21677134
[TBL] [Abstract][Full Text] [Related]
10. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Li S; Pal R; Monaghan SA; Schafer P; Ouyang H; Mapara M; Galson DL; Lentzsch S
Blood; 2011 May; 117(19):5157-65. PubMed ID: 21389327
[TBL] [Abstract][Full Text] [Related]
11. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
12. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
[TBL] [Abstract][Full Text] [Related]
14. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
[TBL] [Abstract][Full Text] [Related]
15. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.
Aldinucci D; Celegato M; Borghese C; Colombatti A; Carbone A
Br J Haematol; 2011 Jan; 152(2):182-90. PubMed ID: 21114485
[TBL] [Abstract][Full Text] [Related]
16. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
Armellini A; Sarasquete ME; García-Sanz R; Chillón MC; Balanzategui A; Alcoceba M; Fuertes M; López R; Hernández JM; Fernández-Calvo J; Sierra M; Megido M; Orfão A; Gutiérrez NC; González M; San Miguel JF
Br J Haematol; 2008 Apr; 141(2):212-5. PubMed ID: 18353163
[TBL] [Abstract][Full Text] [Related]
17. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
[TBL] [Abstract][Full Text] [Related]
19. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Morgan G
Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
[TBL] [Abstract][Full Text] [Related]
20. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]